Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
SRK Capital Sean Kirkwood | “ImmuCell Corporation ($ICCC) is an animal health company focused on developing and commercializing preventative biological products, led by its flagship First Defense franchise that treats calf scours (severe neonatal diarrhea in dairy and beef calves). The manager's bullish investment thesis centers on a clean corporate turnaround following the strategic abandonment of the capital-intensive Re-Tain drug development program. This exit eliminates an expensive operational drag and allows management to focus entirely on expanding its highly profitable, market-leading First Defense biological line. From a financial and economic perspective, ImmuCell operates with an attractive economic moat supported by customer loyalty and proprietary manufacturing processes. The business is experiencing significant operating leverage as fixed manufacturing facilities reach higher utilization, driving gross margins up to 45%. Removing the Re-Tain R&D burden allows revenue gains to flow directly to EBITDA, which the manager forecasts will reach $12 million to $14 million on $35 million to $40 million in annualized sales. Furthermore, substantial net operating loss (NOL) carryforwards protect these earnings from corporate tax leakage, yielding strong free cash flow conversion. Key upcoming catalysts include the completion of the facility refit to increase monthly production capacity beyond 450,000 units and ongoing commercial market share expansion in U.S. scours biologicals. Downside risks to monitor include execution delays during the facility retrofitting and manufacturing yield disruptions.” | BULL | Q2 2026 Aug 1, 2026 | View Pitch |
Minot Light Capital Partners Tom Wetherald and Eddie Reilly | “ImmuCell is a $65mm market cap animal health company whose core franchise is the First Defense line of products, which protect newborn calves against scours, a leading cause of death for young calves.” | BULL | Q1 2026 Apr 29, 2026 | View Pitch |
SRK Capital Sean Kirkwood | “ImmuCell's thesis remains intact following record first quarter results. The highlight of the quarter was the expansion in gross margins to 42%, resulting in record net income and cash flow. Management is targeting further expansion of gross margins to 45% and it appears this is within sight as there hasn't been a contamination issue since last April and production has been operating at full capacity for two quarters in a row now. With production stabilized, the sales team is now able to pivot to bringing in new business from both existing products and the expansion into the new bulk powder First Defense product line. This new scours product will be targeted at large calf raising ranches that don't individually dose calves for scours prevention, introducing a new market that the company historically has not served. On the mastitis side of the business, Re-Tain's FDA license is still in limbo pending a facility inspection approval at their contract manufacturer. Although the continued delay is frustrating, the company has received authorization for investigational use of Re-Tain. This will allow ImmuCell to market the product for use and receive valuable customer feedback and data. Results of this investigational use should be available around year-end, providing valuable information to bring on a potential strategic partner for a full-scale commercial launch. I believe that ImmuCell is at a major inflection point, with scours production finally stabilized and the impending FDA approval of Re-Tain, there is a prime opportunity for any talented executive to take over the reigns with a clear path to create immense value for themselves and shareholders in the immediate future. Clearly, I am still very optimistic about the upside for ICCC as it currently is valued at a single digit multiple of earnings with near term optionality to unlock significant value through the eventual FDA approval of Re-Tain and continued growth of First Defense. BSD Analysis: ImmuCell is a small-cap animal health name where the core question is whether it can consistently deliver differentiated products with regulatory and manufacturing reliability. Animal health can be attractive because demand is tied to livestock economics and herd health management, not consumer gadgets. The upside is meaningful if the company has products that improve productivity or reduce disease costs for farmers—ROI sells in agriculture. The risk is that small-cap life sciences operations are vulnerable to manufacturing disruptions, regulatory delays, and lumpy order patterns. Investors should watch cash burn, product availability, and whether distribution partnerships are expanding rather than stalling. If execution stabilizes, the stock can surprise because expectations are often low for micro-cap bioscience names. This is a “prove it every quarter” story more than a narrative stock.” | BULL | Q2 2025 Aug 1, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
